RayzeBio
Signal active
Organization
Contact Information
Overview
RayzeBio is focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. As the emerging leader in radiopharmaceuticals, RayzeBio is developing an innovative robust pipeline against validated oncology drug targets to deliver radioisotopes that emit alpha particles such as Actinium-225.
About
Industries
Biotechnology, Health Care, Pharmaceutical, Medical Device
Founded
2018
Employees
51-100
Headquarters locations
United States, North America
Social
N/A
Profile Resume
RayzeBio headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Medical Device sector. The company focuses on Biotechnology and has secured $26.8B in funding across 64 round(s). With a team of 51-100 employees, RayzeBio is actively contributing to advancements in Biotechnology. Their latest funding round, Series D - RayzeBio, raised $160.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
4
Investors
7
Lead Investors
0
Total Funding Amount
$418.0M
Details
4
RayzeBio has raised a total of $418.0M in funding over 4 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2020 | Early Stage Venture | 45.0M | ||
| 2020 | Early Stage Venture | 105.0M | ||
| 2021 | Late Stage Venture | 108.0M | ||
| 2022 | Late Stage Venture | 160.0M |
Investors
RayzeBio is funded by 48 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Viking Global Investors | - | FUNDING ROUND - Viking Global Investors | 160.0M |
| Ally Bridge Group | - | FUNDING ROUND - Ally Bridge Group | 160.0M |
| RayzeBio | - | FUNDING ROUND - RayzeBio | 160.0M |
| Soleus Capital | - | FUNDING ROUND - Soleus Capital | 160.0M |
Recent Activity
There is no recent news or activity for this profile.